Latest 10-Q quarterly reports

Canton Strategic Holdings reports a significant increase in net loss for Q1 2026, primarily driven by its digital asset strategy and substantial unrealized losses on its Canton Coin holdings.

The Greater Cannabis Company, Inc. filed its Q1 2026 10-Q, reporting a net loss of $33,376 and minimal cash, while detailing its strategic shift towards cannabinoid therapeutics and ongoing clinical trial preparations.

OSR Holdings reported a 36% decrease in net sales for Q1 2026, but saw gross profit margins improve to 33% due to a shift to a consignment model.

SEATech Ventures Corp. reports minimal financial activity and net profit for Q1 2026, highlighting ongoing efforts to secure financing and generate revenue.

Onconetix reports a significant revenue decline and substantial goodwill impairment in Q1 2026, while progressing with the Realbotix merger and facing ongoing going concern doubts.

Triller Group Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $32.2 million and a significant decrease in operating expenses, while highlighting ongoing efforts to regain Nasdaq compliance and secure future funding.

Fate Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing financial results, ongoing clinical development, and risk factors.

Vor Biopharma Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial condition, results of operations, and cash flows, with a significant focus on the development of its lead product candidate, telitacicept.

Astrotech Corporation reported a decrease in revenue for the third quarter of fiscal year 2026, with a strategic shift from research and development to sales initiatives.

Intelligent Bio Solutions Inc. announced its third-quarter fiscal year 2026 results, showcasing a 46% year-over-year revenue increase driven by new customer acquisition and strong re-order rates for consumables.

Lite Strategy Inc. reports significant shift towards digital asset treasury strategy, with substantial digital asset holdings and related income/losses impacting financial results.

QT Imaging Holdings, Inc. reported a significant increase in revenue for the first quarter of 2026, driven by higher scanner sales, alongside continued investment in R&D and SG&A.

Protara Therapeutics reports increased R&D spending and a net loss for Q1 2026, while advancing its TARA-002 and IV Choline Chloride programs.

Tyra Biosciences details Q1 2026 financial results, highlighting increased R&D spending and a strong cash position, while advancing its FGFR-targeted drug candidates.

Century Therapeutics reports a significant drop in collaboration revenue and continued operating losses in its Q1 2026 filing, while highlighting progress in its iPSC cell therapy pipeline.

Vishay Intertechnology Inc. announced a significant increase in net revenues and a return to profitability in its first fiscal quarter of 2026, driven by higher sales volumes across its segments.

Gyrodyne LLC reports a slight increase in net assets in liquidation for Q1 2026, with ongoing efforts to maximize property values and navigate legal challenges, while projecting liquidation completion by year-end 2028.

LiqTech International reported a 10.4% decrease in revenue for Q1 2026 compared to the prior year, but saw a significant improvement in gross profit margin due to a favorable product mix and better manufacturing utilization.

Paysign, Inc. announced a significant increase in total revenues and net income for the first quarter of 2026, driven by substantial growth in its pharma and plasma industries segments.

Abeona Therapeutics Inc. reported its first quarter 2026 financial results, highlighting $8.7 million in product revenue from ZEVASKYN and a net loss of $17.1 million.

Arbutus Biopharma reports a significant financial turnaround driven by a $950 million noncontingent settlement payment from Moderna, leading to a substantial net income and a strong cash position.

Alto Neuroscience reports a significant increase in R&D expenses for Q1 2026, driven by advancements in its ALTO-101 and ALTO-207 programs, alongside substantial capital raised through private placements.

Marathon Bancorp, Inc. reported a significant increase in net income for the third quarter of fiscal year 2026, driven by higher net interest income and growth in its loan portfolio.

Xtant Medical Holdings reported a 37% decrease in total revenue for the first quarter of 2026 compared to the prior year, primarily due to asset divestitures and a reduction in license revenue.

Lake Superior Acquisition Corp. reports Q1 2026 results, with net income driven by trust account interest, and details progress on its proposed merger with Openmarkets Group Pty Ltd.

Upstream Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing continued investment in its lead drug candidate, verekitug, and reporting a net loss.

Charlotte's Web Holdings, Inc. reported a 9.0% decrease in revenue for the first quarter of 2026 compared to the prior year, alongside a significant increase in the fair value loss of financial instruments, while awaiting shareholder approval for a major transaction with British American Tobacco.

Protalix BioTherapeutics reports a significant increase in total revenue for Q1 2026, driven by license and R&D services, alongside a substantial improvement in operating income.

Milestone Pharmaceuticals Inc. reported its first quarter 2026 financial results, marking the initial product revenue from CARDAMYST and detailing ongoing clinical development for AFib-RVR.

Avalo Therapeutics announced positive Phase 2 data for abdakibart in hidradenitis suppurativa and completed a significant follow-on offering, bolstering its financial position.